Anuj Marathe1, Sameer Allahabadi2, Alaa Abd-Elsayed3, Michael Saulino4, Jonathan M Hagedorn5, Vwaire Orhurhu6, Jay Karri7. 1. Department of Physical Medicine and Rehabilitation, Baylor College of Medicine, Houston, TX, USA. anuj.marathe@bcm.edu. 2. TCU & UNTHSC School of Medicine, Fort Worth, TX, USA. 3. Department of Anesthesia, Division of Pain Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA. 4. Department of Rehabilitation Medicine, Moss Rehab and Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA. 5. Department of Anesthesiology and Perioperative Medicine, Division of Pain Medicine, Mayo Clinic, Rochester, MN, USA. 6. Department of Anesthesia, Division of Pain Medicine, University of Pittsburgh Medical Center, Susquehanna, PA, USA. 7. Department of Physical Medicine and Rehabilitation, Baylor College of Medicine, Houston, TX, USA.
Abstract
PURPOSE OF REVIEW: Intrathecal drug delivery is a well evidenced strategy for the treatment of many chronic pain syndromes. While opioids, anesthetics, and ziconotide are the most commonly used agents, intrathecal baclofen (ITB), which is indicated to treat spasticity, is also thought to have some analgesic properties that are poorly understood. These analgesic benefits have been reported with ITB use in treating patients with central neurological disorders who suffer from severe spasticity and chronic pain. Our review aims to characterize ITB's effects on pain, function, and quality of life in patients with severe spasticity. We performed a systematic review based on the Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) guidelines. The primary outcome parameters were analgesic relief and functional improvements. Secondarily, quality of life and adverse effects were also recorded. RECENT FINDINGS: After an initial survey identified 393 studies, 20 studies met final inclusion criteria. Of these, 16 utilized ITB monotherapy and 4 utilized ITB polyanalgesia. Overall, there was a paucity of high-powered studies. Mean titrated ITB doses ranged from 140 to 627.9 μg daily. Nineteen studies reported improved pain and spasticity. Seven studies reported improved functional outcomes and quality of life. Our results show that ITB may be an effective agent in treatingfor the treatment of chronic pain in patients with severe spasticity independent of its spasmolytic effects. Although this evidence was largely derived from studies lacking clearly defined outcomes of pain relief, ITB is reasonable to consider for concurrent spasticity and pain management. Well-designed studies are still needed to characterize ITB's analgesic efficacy when used in patients with severe spasticity.
PURPOSE OF REVIEW: Intrathecal drug delivery is a well evidenced strategy for the treatment of many chronic pain syndromes. While opioids, anesthetics, and ziconotide are the most commonly used agents, intrathecal baclofen (ITB), which is indicated to treat spasticity, is also thought to have some analgesic properties that are poorly understood. These analgesic benefits have been reported with ITB use in treating patients with central neurological disorders who suffer from severe spasticity and chronic pain. Our review aims to characterize ITB's effects on pain, function, and quality of life in patients with severe spasticity. We performed a systematic review based on the Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) guidelines. The primary outcome parameters were analgesic relief and functional improvements. Secondarily, quality of life and adverse effects were also recorded. RECENT FINDINGS: After an initial survey identified 393 studies, 20 studies met final inclusion criteria. Of these, 16 utilized ITB monotherapy and 4 utilized ITB polyanalgesia. Overall, there was a paucity of high-powered studies. Mean titrated ITB doses ranged from 140 to 627.9 μg daily. Nineteen studies reported improved pain and spasticity. Seven studies reported improved functional outcomes and quality of life. Our results show that ITB may be an effective agent in treatingfor the treatment of chronic pain in patients with severe spasticity independent of its spasmolytic effects. Although this evidence was largely derived from studies lacking clearly defined outcomes of pain relief, ITB is reasonable to consider for concurrent spasticity and pain management. Well-designed studies are still needed to characterize ITB's analgesic efficacy when used in patients with severe spasticity.
Authors: Meta N Eek; Kristina Olsson; Karin Lindh; Berit Askljung; Magnus Påhlman; Olle Corneliusson; Kate Himmelmann Journal: Dev Med Child Neurol Date: 2017-11-17 Impact factor: 5.449
Authors: Daniel Guillaume; Anthony Van Havenbergh; Michael Vloeberghs; Joan Vidal; Geir Roeste Journal: Arch Phys Med Rehabil Date: 2005-11 Impact factor: 3.966
Authors: M A van Rijn; A G Munts; J Marinus; J H C Voormolen; K S de Boer; I M Teepe-Twiss; N T van Dasselaar; E M Delhaas; J J van Hilten Journal: Pain Date: 2009-02-18 Impact factor: 6.961
Authors: Jose De Andres; Salim Hayek; Christophe Perruchoud; Melinda M Lawrence; Miguel Angel Reina; Carmen De Andres-Serrano; Ruben Rubio-Haro; Mathew Hunt; Tony L Yaksh Journal: Front Pain Res (Lausanne) Date: 2022-06-16